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Antifungal susceptibility testing of yeast isolated from
corneal infections
INTRODUTION
Fungi are opportunistic agents which rarely infect healthy corneas of
immunocompetent individuals. Systemic and local underlying diseases may
render the corneal tissues susceptible to infections with these organisms(1).
Trauma, specially related to organic materials, topical use of steroids and
antibiotics(2-3), contact lens wear, surgical procedures, contamination of
eye solutions, inappropriate maintenance of contact lenses(4), systemic
infections as well as any disease associated with immunodeficiency are
considered risk factors for fungal eye infections(5).
In Brazil, the incidence of fungal eye infections ranges from 3.8 to 10%,
depending on the site of the infection, the diagnostic tools available for
fungal infections in the medical center and the seasons related to the
studied period(6-9).
The occurrence of keratomycosis is of great importance, not only be-
cause of diagnostic problems but also due to the severity of clinical mani-
festations and poor outcome despite antifungal treatment. The severity and
progression of the fungal infection usually depend on the existence of
Purpose: To report the antifungal susceptibility profile of yeast isolates
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strains isolated from corneal infections to amphotericin B, fluconazole,
itraconazole and ketoconazole was performed using the NCCLS broth
microdilution assay. Results: Most episodes of eye infections were
caused by Candida albicans. The antifungal drugs tested showed the
following minimal inhibitory concentration values against yeast isolates:
0.125-0.5 µg/ml for amphotericin B; 0.125->64.0 µg/ml for fluconazole;
0.015-1.0 µg/ml for itraconazole and 0.015-0.125 µg/ml for ketoconazole.
Despite the fact that all Candida isolates were judged to be susceptible to
azoles, one isolate showed a minimal inhibitory concentration value
significantly higher than a 90% minimal inhibitory concentration of all
tested isolates. Rhodotorula rubra was resistant to fluconazole and
itraconazole. Conclusions: Despite the fact that most yeast isolates from
corneal infections are usually susceptible to amphotericin B and azoles,
they exhibit a wide range of minimal inhibitory concentration values for
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determining the concentration to be used in topical antifungal formulations
in order to optimize therapeutic response in eye infections.
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previous underlying diseases, impaired local defense mecha-
nisms and the involved fungal species(10-11).
Therapeutic failure rates in fungal keratitis are very high in
different series and the poor outcome is related to several
factors including: late diagnosis, host’s underlying diseases,
reduced ocular drug penetration and low antifungal suscepti-
bility of certain etiologic agents(2,10,12-15).
Despite the fact that fungal eye infections continue to be a
challenge to ophthalmologists due to the high rates of thera-
peutic failures(16) observed in different services, we found few
studies referring to in vitro antifungal susceptibility testing
of clinical fungal isolates obtained from episodes of eye
infections(16).
The purpose of this study was to evaluate the antifungal
susceptibility profile of yeast isolates from corneal infections
using the internationally accepted NCCLS methodology.
METHODS
From 1996 to 1998, corneal yeast infections were diagno-
sed in 15 patients attended at the External Eye Disease and
Corneal Services of the Department of Ophthalmology, of the
Federal University of São Paulo. Isolation of the involved
etiologic agent as well as the stocking of the specimens were
performed at the Laboratory of Microbiology of this depart-
ment. The patients’ main demographic and clinical data were
obtained by reviewing their charts.
All yeast isolates were submitted to species identification
and in vitro antifungal susceptibility tests at the Special
Mycology Laboratory of the Division of Infectious Diseases
of the Department of Medicine.
Identification of the yeast was based on their micromor-
phology on Cornmeal-Tween 80 agar and their biochemical
profile was determined by assimilation and carbohydrate
fermentation tests(17).
Antifungal susceptibility tests were performed using the
broth microdilution assay according to the methodology re-
commended by the NCCLS (1997)(18). The following antifungal
drugs, supplied by the manufacturers as pure standard com-
pounds, were tested: amphotericin B, fluconazole, itraconazo-
le and ketoconazole. Briefly, the medium used was RPMI-1640,
with L-glutamine, without bicarbonate, and buffered at pH 7.0
with 0.165 M MOPS. The yeast inoculum was prepared based
on optical density using a spectrophotometer to obtain a
yeast concentration of 0.5 - 2.5 x 103 cells/ml. The assays were
incubated at 35°C for 48 h. The minimal inhibitory concentra-
tion (MIC) for amphotericin B was considered the lowest
tested concentration able to inhibit any visual colony growth.
MIC for azoles was considered the lowest concentration able
to inhibit 50% colony growth relative to control.
The breakpoints used for the definition of susceptibility ca-
tegories are those proposed by the NCCLS and are as follows:
Fluconazole: susceptible if MIC < 8.0 µg/ml, dose depen-
dent susceptibility (DD-S) if MIC from 16.0 to 32.0 µg/ml and
resistant if MIC > 64.0 µg/ml;
Itraconazole: Susceptible if MIC < 0.125 µg/ml, dose-de-
pendent susceptibility if MIC from 0.25 to 0.50 µg/ml and
resistant if MIC > 1.0 µg/ml.
Due to a lack of consensus about the definition of MIC
breakpoint for ketoconazole and amphotericin B, arbitrary
values were established according to suggested values of
previous studies:
Ketoconazole: susceptible for isolates with < 0.125 µg/ml,
DD-S for isolates with MIC between 0.25 and 0.50 µg/ml and
resistant for isolates with MIC > 1.0 µg/ml;
Amphotericin B: susceptible if MIC < 1.0 µg/ml and resis-
tant if MIC > 2.0 µg/ml.
RESULTS
Clinical and epidemiological characteristics of the evalua-
ted patients are summarized in Table1.
The patients’ ages ranged from 10 to 89 years, with a
median age of 64 years, x = 56.4) with 6 episodes (40%)
occurring in males. It was possible to identify one or more
predisposing factors for eye infection in all enrolled patients,
with an emphasis on local immunosuppression as well as the
use of topical antibiotics.
The species distribution of the yeast isolates, as shown in
Table 1, was the following: C. albicans (53.3%), C. parapsilo-
sis (20.0%), C. tropicalis (20.0%) and one case of Rhodotoru-
la rubra.
The MIC values of antifungal drugs tested are shown in Table 2.
The MIC values of the antifungal drugs tested against
Candida spp isolates ranged from 0.125 to 0.5 µg/ml for
amphotericin B, 0.125 to 4.0 µg/ml for fluconazole, 0.015 to 0.25
µg/ml for itraconazole and 0.015 µg/ml to 0.06 µg/ml for keto-
conazole.
Using the susceptibility breakpoints suggested by the
NCCLS(21) for the studied antifungal drugs, it was possible to
state that all samples were susceptible to amphotericin B.
Regarding azoles, the Rhodotorula rubra isolate was resis-
tant to fluconazole and itraconazole. Similarly, one C. albi-
cans strain exhibited dose-dependent susceptibility to itraco-
nazole. It should be mentioned that although all Candida
isolates were susceptible to fluconazole, one C. albicans
isolate showed a MIC value of 2.0 µg/ml (patient 3) for fluco-
nazole and one C. parapsilosis strain exhibited a MIC value of
4.0 µg/ml for fluconazole (patient 10).
Table 3 summarizes the MIC ranges, MIC-50% (concentra-
tion able to inhibit 50% colony growth (or colony formation)
of the tested samples) and MIC-90% (concentration able to
inhibit 90% colony growth (or colony formation) of the tested
samples) values of antifungal drugs tested against all C. albi-
cans isolates.
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Table 1. Clinical, epidemiological and laboratory data of 15 episodes of corneal infections attended at the Department of Ophthalmology,
UNIFESP – EPM (1996 to 1998)
No. Age (years) Sex Predisposing factors Site Microorganism
1 74 F Corneal surgery - Tx Cornea C. albicans
2 45 F Trauma – Foreing body Cornea C. albicans
3 81 M Exposed ulcer Cornea C. albicans
4 89 F Senility Cornea C. albicans
5 69 M Corneal perforation Cornea C. albicans
6 47 M Endophthalmitis/keratitis Cornea C. albicans
7 44 F Immunosuppression Sjögren S. Cornea C. albicans
8 44 M Immunosuppression HIV + Cornea C. albicans
9 70 F Corneal surgery - ulcer Cornea C. parapsilosis
10 83 F Use of topical medication Cornea C. parapsilosis
11 48 F Corneal surgery – Tx Cornea C. parapsilosis
12 14 M Trauma Cornea C. tropicalis
13 64 F Surgery - Tx Cornea C. tropicalis
14 64 F Surgery - Tx Cornea C. tropicalis
15 10 M Dermatological alteration Cornea Rhodotorula rubra
F - Female; M - Male; Tx - Corneal transplantation; C. - Candida
DISCUSSION
Although mycotic keratitis may occur in a variety of clima-
tic zones, it seems to be more common in regions with subtro-
pical or tropical climate, both found in the greater part of
Brazil. Fungi accounted for 5% of all infectious keratitis (61 of
1113 patients) as documented in the Laboratory of External
Diseases of the Department of Ophthalmology, Federal Uni-
versity of São Paulo - Escola Paulista de Medicina, from 1995
to 1998 (data not shown). Fusarium genus (51%), Candida
spp (23%) and Aspergillus spp (8.19%) were the most com-
monly isolated agents of fungal keratitis(19).
In the present study, the clinical and microbiological cha-
racteristics of documented yeast keratitis were evaluated at
the institution. In agreement with other series, all patients
with yeast corneal infections presented with at least one
predisposing factor to corneal fungal infections, including
the use of antibiotics and corticoids, systemic immunosup-
pression, advanced age, trauma or previous surgery.
Regarding the etiology of the eye infections, 53.3% was
keratitis caused by C. albicans. This finding is in agreement
with previous publications addressing the etiology of eye
infections. Rosa et al.(19) reviewed the charts of 125 patients
with fungal keratitis in South Florida for a period of 10 years
(1982-1992) and observed that the Candida genus accounted
for 12% (16 cases) of all infections. Regarding species,
C. albicans corresponded to 25%(20). Wakisaka et al, after
analyzing the cultures of corneal ulcers in 263 patients, from
Table 2. Minimal inhibitory concentration (MIC) values of 4 antifungal drugs tested on 15 yeast specimens
MIC values (µg/ml)
No. Amphotericin-B Fluconazole Itraconazole Ketoconazole Microorganisms
1 0.25 0.5 0.03 0.015 C. albicans
2 0.25 2.0 0.25 (I) 0.06 C. albicans
3 0.125 0.25 0.015 0.015 C. albicans
4 0.5 0.25 0.03 0.03 C. albicans
5 0.125 0.125 0.06 0.015 C. albicans
6 0.5 0.125 0.015 0.015 C. albicans
7 0.25 0.125 0.015 0.015 C. albicans
8 0.5 0.25 0.03 0.03 C. albicans
9 0.25 0.5 0.06 0.015 C. parapsilosis
10 0.125 4.0 0.06 0.06 C. parapsilosis
11 0.5 0.5 0.03 0.015 C. parapsilosis
12 0.25 0.25 0.015 0.015 C. tropicalis
13 0.125 1.0 0.06 0.03 C. tropicalis
14 0.25 0.125 0.015 0.015 C. tropicalis
15 0.25 >64 ® 1.0 ® 0.125 R. rubra
MIC – Minimal inhibitory concentration; C. – Candida; R. Rhodotorula; ® – Resistant; (I) – Dose dependent susceptibility
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September,1986 to February,1998, found 10 episodes of
mycotic keratitis (4%) where 2 cases were caused by C.
albicans isolates(6). In this laboratory, a retrospective study
was conducted to evaluate 671 cases of infectious corneal
ulcers reported during a period of 10 years (January, 1981 to
December, 1991). The authors found that 64 episodes (1.5%)
were caused by fungi and Candida sp accounted for 12.5% of
all identified fungal isolates(9).
It is interesting that we were able to identify one case of
keratitis due to Rhodotorula rubra, an agent of low pathoge-
nicity and virulence, causing corneal infection. We did not
find any previous report of keratitis caused by this yeast
pathogen. However, different authors view this agent as
being an emergent pathogen among superficial and systemic
fungal infections(21-23).
To enhance drug penetration and clinical efficacy, keratitis
therapy involves the use of topic, systemic and subconjuncti-
val medication after removal of the corneal epithelium. Topical
amphotericin B is considered to be the drug of choice for the
treatment of mycotic keratitis(24). The range of amphotericin B
concentrations in topic formulations used for the treatment of
corneal infections is very broad. Experiments have shown that
concentrations between 0.015 and 1% may be used. Amphote-
ricin B is toxic when administrated by the subconjunctival
route and severe complications, including conjunctival necro-
sis, may occur(14). Intravenous use of amphotericin B is limited
in the case of fungal keratitis because, besides all the systemic
adverse effects, it penetrates the cornea minimally reaching
low levels in the aqueous humor(15). After evaluating the sus-
ceptibility profile of amphotericin B obtained with the tested
clinical yeast isolates, we found that all were susceptible to
this drug; however, a MIC variation of 0.125 µg/ml to 0.5 µg/ml
was observed. Considering the range of MIC obtained with
amphotericin B, to optimize the clinical efficacy of topic formu-
lations and avoid toxicity, it would be reasonable to propose
that patients infected with agents with higher susceptibility to
this drug should be treated with lower concentrations and
vice-versa. This notion needs to be validated by clinical and
experimental studies which are only possible with the use of
susceptibility tests applied to ocular pathogens.
Ketoconazole is an imidazole to be used orally, truly requi-
ring systemic absorption which depends on the gastric
acidity. Topical formulations of ketoconazole may be prepared
at a 1 to 5% concentration, reaching good therapeutic corneal
levels. Since ketoconazole can be administered orally and
shows a wide antifungal spectrum, the drug is a natural candi-
date for use in the systemic treatment of keratomycosis, either
alone or in association with topic preparations(15). In the pre-
sent study, the isolates were all susceptible to ketoconazole
but exhibited MIC values ranging from 0.015 to 0.125 µg/ml, a
variation of almost 100 times the inhibitory potential of this
drug in relation to the examined pathogens.
Fluconazole is a triazole exhibiting excellent tolerability
and intraocular penetration. However, its antifungal activity is
basically restricted to the genus Candida, C. neoformans
isolates and dermatophytes. It is important to note that fluco-
nazole has no antimycotic activity against Aspergillus spp
and Fusarium spp, the agents which usually cause kerati-
tis(15,25). Regarding fluconazole MIC, we obtained a large va-
riation of values against the tested ocular pathogens, inclu-
ding one C. albicans strain that exhibited a MIC value higher
than the MIC-90 for the 8 tested samples (Table 3). On the
other hand, there was one episode of R. rubra keratitis in
which the isolate exhibited in vitro resistance to fluconazole
and itraconazole. These data reinforce the potential role of
susceptibility tests in defining a rational therapeutic strategy
for fungal keratitis.
Itraconazole is a triazole with a large spectrum of antifun-
gal activity including activity against the genus Candida, C.
neoformans isolates, as well as dermatophytes, Aspergillus
spp and dimorphic fungi. However, the capsule formulation
available shows bioavailability limitations affecting its serum
levels and tissular distribution. Therefore, in spite of its high
tolerability and broad spectrum, its clinical ophthalmologic
use is restricted(25-26). In the present study, MIC values for
itraconazole were quite lower than those recorded for flucona-
zole when we evaluated Candida spp specimens. These data
reinforce the therapeutic potential of itraconazole in fungal
keratitis, whose clinical applicability could be broadened with
the recent advent of oral and parenteral solutions of this
derivative solubilized in cyclodextrin(27).
Recently, several studies have called attention to the
occurrence of primary or acquired infections due to yeast
resistant to antifungal drugs. Such reports are more frequent
among patients with AIDS or malignant hematological disea-
ses, situations in which the prophylactic or therapeutic use of
antimycotics is more disseminated(28-30) The literature includes
many studies which evaluate the susceptibility profile of
yeast isolates from different biological fluids and tissues;
however, none were found describing the antifungal suscepti-
bility profile of yeast isolates from ocular infections (31-35).
Considering the high therapeutic failure rate associated
with ocular fungal infections, the investigation of the antifun-
Table 3. MIC ranges, MIC 50% and MIC 90% values of 4 antifungal drugs against 8 C. Albicans isolates
Variables/Antifungals Amphotericin B Fluconazole Itraconazole Ketoconazole
MIC ranges (µg/ml) 0.125 - 0.5 0.125 - 2.0 0.015 - 0.25 0.015 - 0.06
MIC - 50% 0.25 0.25 0.03 0.015
MIC - 90% 0.50 0.50 0.06 0.03
MIC – Minimal inhibitory concentration
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gal susceptibility profile of ocular fungal pathogens may be
useful to identify antifungal resistance as a possible risk
factor for unfavorable outcome. Similarly, to optimize the toxi-
city/therapeutic efficacy ratio with respect to ocular infec-
tions, it is reasonable to suggest that MIC values of antifun-
gal drugs should be considered before defining the best con-
centration of the drug to be used in topic formulations. The
actual benefit of such management should be evaluated by
further clinical studies.
CONCLUSIONS
In conclusion, in spite of the fact that most yeast isolates
from ocular infections were found to be susceptible to ampho-
tericin B and azoles, a wide variation of antifungal MIC values
were obtained with the various tested pathogens. These data
provide a warning to reference laboratories associated with
Ophthalmology Services that they should be prepared not
only for the accurate identification of the fungi found in
biological fluids, but also for determination of their suscepti-
bility to antifungal drugs as an additional tool to support
therapy.
RESUMO
Objetivo: Relatar resultados e avaliar a aplicabilidade do teste
de suscetibilidade a antifúngicos de leveduras isoladas de
infecções corneais oculares. Métodos: Realizou-se teste de
suscetibilidade pelo método de microdiluição em caldo, padro-
nizado pelo NCCLS-EUA, em 15 amostras de leveduras de
infecções corneanas a anfotericina B, fluconazol, itraconazol e
ketoconazol. Resultados: A maioria dos episódios de infecção
corneal foi causada por Candida albicans. As drogas antifún-
gicas testadas exibiram valores de concentração inibitória mí-
nima (CIM) para as leveduras isoladas: 0,125-0,5 µg/ml para
anfotericina B; 0,125->64,0 µg/ml para fluconazol; 0,015-1,0 µg/ml
para itraconazol e 0,015-0,125 µg/ml para ketoconazol. Apesar
de todas as amostras terem sido suscetíveis aos azólicos, uma
exibiu valor de concentração inibitória mínima significante-
mente maior do que a concentração inibitória mínima 90% de
todas as amostras testadas. Rhodotorula rubra foi resistente
a fluconazol e itraconazol. Conclusão: Apesar da maioria das
leveduras isoladas de infecções corneais serem usualmente
suscetíveis a anfotericina B e azólicos, observa-se ampla va-
riação de valores de concentração inibitória mínima obtidas
com as diferentes drogas antifúngicas testadas. A identifica-
ção das cepas e a determinação do padrão de suscetibilidade
devem ser consideradas antes da determinação da concentra-
ção das drogas a ser empregada em formulações antifúngicas
tópicas com o objetivo de otimizar a resposta terapêutica às
infecções oculares.
Descritores: Infecções oculares; Ceratites; Antifúngicos; Infec-
ções por leveduras; Testes de suscetibilidade a antifúngicos.
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